What do systematic reviews say?

DHEA vs HT

The review found no eligible studies for this question.

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DHEA vs HT

It is very uncertain whether DHEA changes acne DHEA versus ET compared with HT (very low certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 17 [0.9, 320.37]
  1 study · 50 participants
  Very low

DHEA vs HT

It is very uncertain whether DHEA changes acne DHEA versus tibolone compared with HT (very low certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 17 [0.9, 320.37]
  1 study · 50 participants
  Very low

DHEA vs HT

The review found no eligible studies for this question.

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DHEA vs HT

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

DHEA vs placebo or control

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 287 participants
  Moderate

DHEA vs placebo or control

DHEA probably leads to higher side effects (androgenic overall combined with acne) number of events compared with control (placebo or no treatment) (moderate certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 3.77 [1.36, 10.47]
  5 studies · 250 participants
  Moderate

DHEA vs placebo or control

DHEA may leads to higher side effects ‐ androgenic side effects number of events compared with control (placebo or no treatment) (low certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 6.57 [1.37, 31.59]
  1 study · 92 participants
  Low

DHEA vs placebo or control

DHEA showed no clear difference in side effects ‐ acne number of events compared with control (placebo or no treatment) (moderate certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 2.26 [0.56, 9.02]
  4 studies · 158 participants
  Moderate

DHEA or testosterone vs placebo/no treatment

DHEA or testosterone probably leads to higher live birth/ongoing pregnancy rate ‐ DHEA compared with placebo/no treatment (moderate certainty).

• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 1.81 [1.25, 2.62]
  8 studies · 878 participants
  Moderate
• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 2.6 [1.3, 5.2]
  4 studies · 345 participants
  Moderate

DHEA or testosterone vs placebo/no treatment

DHEA or testosterone showed no clear difference in miscarriage rate ‐ DHEA compared with placebo/no treatment (moderate certainty).

• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 0.58 [0.29, 1.17]
  8 studies · 950 participants
  Moderate

DHEA or testosterone vs placebo/no treatment

DHEA or testosterone probably leads to higher clinical pregnancy rate ‐ DHEA compared with placebo/no treatment (moderate certainty).

• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 1.34 [1.01, 1.76]
  12 studies · 1246 participants
  Moderate

DHEA or testosterone vs placebo/no treatment

It is very uncertain whether DHEA or testosterone changes multiple pregnancy ‐ DHEA compared with placebo/no treatment (very low certainty).

• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 3.23 [0.13, 81.01]
  5 studies · 267 participants
  Very low
• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 3.09 [0.48, 19.98]
  3 studies · 292 participants
  Very low

Oral DHEA vs control subgrouped by differing routes of administration

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 66 participants
  Very low
• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 107 participants
  Very low

Oral DHEA vs control subgrouped by differing routes of administration

It is very uncertain whether oral DHEA changes side effects: acne ‐ skin application compared with control subgrouped by differing routes of administration (very low certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 2.74 [0.1, 74.87]
  1 study · 22 participants
  Very low

Oral DHEA vs control subgrouped by differing routes of administration

It is very uncertain whether oral DHEA changes side effects: acne ‐ oral administration compared with control subgrouped by differing routes of administration (very low certainty).

• Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
  OR 2.16 [0.47, 9.96]
  3 studies · 136 participants
  Very low

DHEA or testosterone vs placebo/no treatment

DHEA or testosterone showed no clear difference in miscarriage rate ‐ Testosterone compared with placebo/no treatment (low certainty).

• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 2.04 [0.58, 7.13]
  4 studies · 345 participants
  Low

DHEA or testosterone vs placebo/no treatment

DHEA or testosterone probably leads to higher clinical pregnancy rate ‐ Testosterone compared with placebo/no treatment (moderate certainty).

• Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction 2015 · Cochrane Headline outcomes only
  OR 2.52 [1.36, 4.68]
  4 studies · 345 participants
  Moderate